Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Sulfuric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 known ✓ | P08172 | 1/20 | 0.34 |
| ▸ | CHRM1 known ✓ | P11229 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ammonia Solution, Strong SCHEMBL5698223 | 0.98 | ALDH1A1 (0.43) | ALDH1A1KDM4EHSD11B1KMT2ALMNA | |
| Sulfuric Acid SCHEMBL6545396 | 0.98 | ALDH1A1 (0.43) | ALDH1A1KDM4EHSD11B1KMT2ALMNA | |
| SCHEMBL2229127 | 0.96 | ALDH1A1 (0.45) | ALDH1A1KDM4EHSD11B1KMT2ALMNA | |
| SCHEMBL9790 | 0.96 | ALDH1A1 (0.45) | ALDH1A1KDM4EHSD11B1KMT2ALMNA | |
| SCHEMBL2417 | 0.96 | ALDH1A1 (0.45) | ALDH1A1KDM4EHSD11B1KMT2ALMNA | |
| SCHEMBL21752977 | 0.94 | ALDH1A1 (0.43) | ALDH1A1KDM4EHSD11B1KMT2ALMNA | |
| SCHEMBL21752843 | 0.94 | ALDH1A1 (0.43) | ALDH1A1KDM4EHSD11B1KMT2ALMNA | |
| SCHEMBL3653844 | 0.94 | ALDH1A1 (0.43) | ALDH1A1KDM4EHSD11B1KMT2ALMNA | |
| SCHEMBL21752879 | 0.94 | ALDH1A1 (0.43) | ALDH1A1KDM4EHSD11B1KMT2ALMNA | |
| SCHEMBL21752841 | 0.94 | ALDH1A1 (0.43) | ALDH1A1KDM4EHSD11B1KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4371570-A2 | TREATMENT OF IGG4-RELATED DISEASES WITH ANTI-CD19 ANTIBODIES CROSSBINDING TO CD32B | Xencor, Inc. (US) | 2024-05-22 | — | — | EP | disclosed |
| WO-2023235852-A1 | METHODS AND COMPOSITIONS FOR TREATING IGG4- RELATED DISEASES | ZENAS BIOPHARMA, INC. (US) | 2023-12-07 | — | — | WO | disclosed |
| EP-3468997-B1 | TREATMENT OF IGG4-RELATED DISEASES WITH ANTI-CD19 ANTIBODIES CROSSBINDING TO CD32B | XENCOR INC (US) | 2023-09-13 | — | — | EP | disclosed |
| US-20220389098-A1 | METHODS AND COMPOSITIONS FOR INHIBITING CD32B EXPRESSING CELLS IN IGG4-RELATED DISEASES | XENCOR, INC. (US) | 2022-12-08 | — | — | US | disclosed |
| US-11365256-B2 | Methods and compositions for inhibiting CD32B expressing cells in IGG4-related diseases | XENCOR, INC. (US) | 2022-06-21 | — | — | US | disclosed |
| WO-2020072653-A1 | METHODS AND COMPOSITIONS FOR TREATING IGG4-RELATED DISEASES | ZACK DEBRA (US) | 2020-04-09 | — | — | WO | disclosed |
| EP-3468997-A1 | TREATMENT OF IGG4-RELATED DISEASES WITH ANTI-CD19 ANTIBODIES CROSSBINDING TO CD32B | Xencor, Inc. (US) | 2019-04-17 | — | — | EP | disclosed |
| WO-2017214452-A1 | TREATMENT OF IGG4-RELATED DISEASES WITH ANTI-CD19 ANTIBODIES CROSSBINDING TO CD32B | XENCOR, INC. (US) | 2017-12-14 | — | — | WO | disclosed |
| US-20170355766-A1 | METHODS AND COMPOSITIONS FOR INHIBITING CD32B EXPRESSING CELLS IN IGG4-RELATED DISEASES | XENCOR, INC. (US) | 2017-12-14 | — | — | US | disclosed |
| CN-1922206-A | Process for the preparation of latent antithrombin iii | OCTAPHARMA AG (CH) | 2007-02-28 | — | — | CN | disclosed |
| EP-1332159-A1 | PROCESS FOR THE PREPARATION OF LATENT ANTITHROMBIN III | Octapharma AG (CH) | 2003-08-06 | — | — | EP | disclosed |
| US-20020090711-A1 | Process for preparing latent antithrombin III | OCTAPHARMA AG (CH) | 2002-07-11 | — | — | US | disclosed |
| WO-2002038610-A1 | PROCESS FOR THE PREPARATION OF LATENT ANTITHROMBIN III | OCTAPHARMA AG (CH) | 2002-05-16 | — | — | WO | disclosed |